Bristol-Myers Squibb Co. is paying Aslan Pharmaceuticals Pte. Ltd. $10m upfront to reacquire at an early stage the Asian rights to a first-in-class oncology molecule it originally licensed to the Singapore-based oncology venture back in 2011.
ASLAN will also be eligible for development and regulatory milestones "in excess of" a further $50m, plus royalties on BMS'...






